Is Dapagliflozin (Forxiga) 10mg once daily (OD) in the morning and Glicazide (Diamicron) 60mg once daily in the evening an effective regimen for a patient with type 2 diabetes and mildly elevated glucose level of 7.57 mmol/l?

Dapagliflozin 10mg OD AM and Gliclazide 60mg OD PM for Glucose 7.57 mmol/L

Yes, this combination is appropriate and effective for a patient with type 2 diabetes and a glucose level of 7.57 mmol/L (136 mg/dL), representing a reasonable dual therapy approach that addresses both fasting and postprandial hyperglycemia. 1

Rationale for This Combination

Dapagliflozin 10mg Once Daily

• The standard dose of dapagliflozin is 10mg once daily for glycemic control in type 2 diabetes, which can be initiated if eGFR ≥45 mL/min/1.73 m² 2
• Dapagliflozin provides additional benefits beyond glycemic control, including cardiovascular and renal protection, weight reduction (typically 2-3 kg), and blood pressure lowering (systolic 2-5 mmHg) 3, 4
• For patients with established cardiovascular disease, chronic kidney disease, or heart failure, dapagliflozin 10mg daily is strongly recommended regardless of baseline glucose levels 1, 5

Gliclazide 60mg Once Daily

• Gliclazide modified release 60mg once daily provides effective 24-hour glycemic control with a low risk of hypoglycemia 6
• This sulfonylurea dose is appropriate for patients requiring additional glycemic lowering beyond metformin or SGLT2 inhibitors 1
• Evening administration may be preferable for some patients, though morning dosing is also acceptable 6

Critical Assessment of Current Glucose Level

• A glucose level of 7.57 mmol/L (136 mg/dL) falls within the acceptable fasting glucose target range of 4.4-7.2 mmol/L (80-130 mg/dL) recommended by guidelines 1
• This suggests the current dual therapy regimen is achieving adequate glycemic control 1
• However, you must verify whether this is a fasting glucose or random glucose measurement, as this significantly impacts interpretation 1

Essential Monitoring and Adjustments

Verify Foundation Therapy

• Confirm the patient is on metformin unless contraindicated, as metformin remains the foundation of type 2 diabetes therapy and should be continued when adding or intensifying other agents 1
• If metformin is not being used, it should be added at 500-1000mg twice daily (up to 2000-2500mg/day) unless eGFR <30 mL/min/1.73 m² 1

Renal Function Assessment

• Check eGFR before continuing dapagliflozin and periodically thereafter 5, 2
• Dapagliflozin should not be used for glycemic control if eGFR <45 mL/min/1.73 m², though it can be continued for cardiovascular/renal protection down to eGFR 25 mL/min/1.73 m² 5, 2
• An initial eGFR dip of 3-5 mL/min/1.73 m² within 1-4 weeks is expected and reversible 5

HbA1c Monitoring

• Assess HbA1c every 3 months to determine if the current regimen is achieving glycemic targets (typically <7% for most adults) 1
• If HbA1c remains above target despite fasting glucose of 7.57 mmol/L, this suggests postprandial hyperglycemia requiring additional intervention 1

Important Safety Considerations

Hypoglycemia Risk

• The combination of dapagliflozin and gliclazide carries a moderate risk of hypoglycemia, primarily from the sulfonylurea component 1
• Educate the patient on recognition and treatment of hypoglycemia with 15 grams of fast-acting carbohydrate 1
• If hypoglycemia occurs, reduce gliclazide dose by 10-20% rather than discontinuing dapagliflozin 1

Sick Day Management

• Instruct the patient to withhold dapagliflozin during acute illness, particularly with reduced food/fluid intake, fever, vomiting, or diarrhea 5
• Monitor for euglycemic diabetic ketoacidosis, which can occur even with normal blood glucose levels 5, 2
• Continue at least low-dose insulin if the patient is insulin-requiring, even when dapagliflozin is held 5

Genital Mycotic Infections

• Genital mycotic infections occur in approximately 6% of patients on SGLT2 inhibitors versus 1% on placebo 5, 3
• Counsel patients on daily hygienic measures to reduce this risk 5

Volume Depletion

• Assess volume status before starting dapagliflozin and correct any volume depletion 2
• Consider reducing concurrent diuretic doses to prevent excessive volume depletion 5
• Elderly patients (>65 years) and those on diuretics are at higher risk 5

When to Intensify Therapy

If Glucose Control Remains Inadequate

• If HbA1c remains >7% after 3-6 months on this dual therapy, consider adding a GLP-1 receptor agonist rather than further intensifying with insulin 1
• GLP-1 receptor agonists provide superior glycemic control with weight loss and lower hypoglycemia risk compared to insulin 1

Cardiovascular and Renal Considerations

• If the patient has established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with eGFR 25-75 mL/min/1.73 m² and albuminuria (UACR ≥200 mg/g), dapagliflozin 10mg daily is strongly indicated regardless of glycemic control 1, 5
• These benefits are independent of diabetes status and persist even when glycemic efficacy is lost at lower eGFR levels 5

Common Pitfalls to Avoid

• Do not discontinue dapagliflozin solely because eGFR falls below 45 mL/min/1.73 m², as cardiovascular and renal protective benefits persist even when glycemic efficacy is lost 5
• Do not continue escalating gliclazide doses if hypoglycemia occurs; instead, reduce the sulfonylurea dose and consider adding a GLP-1 receptor agonist 1
• Do not delay insulin initiation if HbA1c remains ≥9% or blood glucose ≥300 mg/dL (16.7 mmol/L) despite dual therapy 1
• Do not forget to withhold dapagliflozin at least 3 days before major surgery or procedures with prolonged fasting 2